Previous close | 12.52 |
Open | 12.49 |
Bid | 11.80 x 500 |
Ask | 11.86 x 500 |
Day's range | 11.81 - 12.49 |
52-week range | 5.67 - 30.99 |
Volume | |
Avg. volume | 1,188,290 |
Market cap | 616.679M |
Beta (5Y monthly) | 1.72 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.81 |
Earnings date | 31 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 40.44 |
On May 14, 2024, David Guyer, Director at EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), executed a sale of 11,625 shares of the company.
WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an a
Comprehensive Analysis of Financial Performance and Strategic Developments